SPY330.65-3.85 -1.15%
DIA276.52-2.38 -0.85%
IXIC10,793.28-117.00 -1.07%

Oppenheimer Maintains Outperform on Vertex Pharmaceuticals, Raises Price Target to $265

Oppenheimer analyst Hartaj Singh maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Outperform and raises the price target from $230 to $265.

Benzinga · 01/08/2020 16:04

Oppenheimer analyst Hartaj Singh maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Outperform and raises the price target from $230 to $265.